APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer
Dr. Shearman, a pharma and biotech industry executive with an extensive track record of achievements in drug discovery and development, will lead the strategy and execution of the company’s clinical